Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial. (linkinghub.elsevier.com)

Authors: Bajaj HS … Bartee A Journal: The Lancet Published: 2026-06-13 DOI: https://doi.org/10.1016/S0140-6736(26)00967-0